Table 3. 2010 AJCC staging system for pNETs.
| Stage | Tumor | Node | Metastasis | Stage specific 5-year survival | |
|---|---|---|---|---|---|
| IA | T1 | N0 | M0 | Stage IA | 96% |
| IB | T2 | N0 | M0 | Stage IB | 92% |
| IIA | T3 | N0 | M0 | Stage IIA | 76% |
| IIB | T1-3 | N1 | M0 | Stage IIB | 73% |
| III | T4 | Any N | M0 | Stage III | - |
| IV | Any T | Any N | M1 | Stage IV | 56% |
Survival data from Ellison TA, et al. (30). SMA, superior mesenteric artery; AJCC, American Joint Committee on Cancer; pNETs, pancreatic neuroendocrine tumors. T1, <2 cm but limited to the pancreas; T2, >2 cm but limited to the pancreas; T3, tumor extends beyond the pancreas but not involving the celiac axis or SMA; T4, tumor involves celiac axis or SMA; N0, no regional lymph node metastases; N1, regional lymph node metastases; M0, no distant metastases; M1, distant metastases.